Webcast: Selecting the Right Materials to Scale Up Production

Building Tomorrow’s Success: A Roadmap to Scaled-up Production

As the demand for cost-effective cell and gene therapies increases, managing the complexity of cell culture is critical to success. For process developers, one aspect that’s critical is to establish key starting materials from reliable suppliers early on. Selecting the right materials can help reduce costs and support seamless process transfer into clinical development.

Tune into this panel discussion and learn:

How raw materials impact your cell culture and final product
What to consider when selecting cytokines, growth factors, and cell culture media to optimize performance, quality, and safety
How partnering with an experienced supplier can streamline the path to clinical production

Clear form data

Please Complete the Form

First Name *

Last Name *

Email *

Phone Number *

Company *

Job Title *

Address *

Country *

Postal Code *

I would like to sign up for newsletters from Sartorius (Sartorius AG and its affiliated companies) based of my personal interests.
I can revoke my consent at any time with effect for the future by sending an e-mail to unsubscribe@sartorius.com or by clicking on the "unsubscribe" link in e-mails I have received.

* These fields are required Information on the use of your data can be found in our privacy policy

Complete Form to Access the File

Andres Castillo

Portfolio Manager | Cell Culture Technologies

Andres Castillo is a Portfolio Manager for Cell Culture Technologies, within the Bioprocess Solutions division at Sartorius. He holds a BS and MBA from the University of Washington. He is working on the execution of Sartorius' global cell culture technology strategy, developing application notes and webinars. Before joining Sartorius in 2021, Andres worked as research scientist in both GMP and non-GMP settings, specializing in cell therapy manufacturing and gene editing applications.

Christoph Heinrich

Head of Operations, Sartorius Xell

Christoph works as the Head of Operations for Sartorius Xell, where he is responsible for X. He earned his Diploma in Biotechnology from Bielefeld University in 2008.
Christoph is an expert in the development, manufacture, and sales of mammalian cell culture media for the global biopharmaceutical and vaccine industry as well as analytical methods, process development, and related quality management topics.
Prior to his current role, Christoph held various positions within Xell, including Scientist, Chief Scientific Officer, and Chief Operating Officer, before Sartorius acquired Xell in 2021.

Felicia Rosenthal

Managing Director at Sartorius CellGenix

As one of the co-founders and first General Manager, Felicia Rosenthal has led CellGenix since 1994. She studied medicine at the University of Mainz and the University College of London, completed a post-doctoral fellowship at Memorial Sloan Kettering Cancer Center, New York, and received her Habilitation for work with retroviral gene transfer in cancer immunotherapy. Felicia obtained her medical specialization in laboratory medicine.
Felicia also holds an executive MBA from the WHU Koblenz and J.L. Kellogg Graduate School of Management at Northwestern University, Chicago. From 2004 until 2013, she served on the management Board of BIO Deutschland, the German Biotechnology Industry Organization, and from 2014 until 2017, on the Board of BIOValley Deutschland, the European Life Sciences Cluster in Southwest Germany.